The COBE Spectrat is used to volume/red blood cell (RBC) deplete BM before transplantation or cryopreservation. We have audited our results to identify the effect of transit time, refrigerated storage, age and cellular composition on mononuclear cells (MNC) and CD34 þ cell recoveries, volume/RBC depletion and neutrophil engraftment. In total, 88 consecutive collections from autologous (n ¼ 25) and allogeneic (n ¼ 63) donors were included. The mean collection volume was 12507 398 ml with RBC content of 3417113 ml. The MNC and CD34 þ cell recoveries were 83.3718.5 and 88.1718.9%, respectively, volume depletion was 88.274.4% and RBC depletion 98.371.8%. Neutrophil engraftment was achieved in 20.176.4 days. Factors affecting MNC and CD34 þ cell recoveries were transit time (P ¼ 0.0060), overall age (Po0.0210) and MNC/CD34 þ cell concentrations (Po0.0313). The presence of crenated RBC also reduced CD34 þ cell recovery (P ¼ 0.0028). Refrigerated storage did not adversely affect cell recovery (P40.8161) or neutrophil engraftment (P ¼ 0.8959). This study demonstrates that time in transit, overall age, MNC and CD34 þ cell concentrations and RBC condition were important factors affecting processing. RBCs show artefacts soon after collection at ambient temperatures and these may interfere with the separation and collection of MNC/CD34 þ cells. Refrigeration at 4-61C during transit and storage may reduce formation of RBC artefacts and maximize MNC and CD34 þ cell recoveries.
Introduction
Bone marrow collections for allogeneic and autologous haematopoietic stem cell transplantation are typically over a litre in volume. In order to reduce the cryogenic storage space required, it is important to volume reduce bone marrow collections before cryopreservation and long-term storage. In addition, allogeneic grafts that are ABO incompatible may be red blood cell (RBC) depleted before infusion to minimize the risk of ABO-induced transfusion reactions. 1 In the procedure, it is important to maximize CD34 þ haematopoietic progenitor cell recovery, as engraftment of haematopoietic stem cells correlates with the dose of CD34 þ cells infused.
2,3
The COBE Spectra cell separator has been used for volume reduction and RBC depletion of bone marrow for over 14 years. It is a continuous flow cell separator that isolates cells initially through centrifugation and the formation of a buffy layer. Mononuclear cells (MNCs) and CD34
þ progenitor cells are collected from the buffy layer through an MNC channel that is maintained in position by pressure differentials in the collection chamber through adjustment of the plasma flow rates. Using the COBE Spectrat, Baker et al. 4 reported in 1991 MNC and colony-forming units-granulocyte-macrophage progenitor cell recoveries of 76.4 and 86.5%, respectively, and volume depletion of 87.0%. In a separate study, Koristek and Mayer 5 reported 78.8% MNC and 77.2% CD34 þ progenitor cell recoveries. These studies showed considerable variation in the recoveries of MNC and CD34 þ cells, ranging from 33 to 260%. Despite this, the factors affecting the recovery of these cells were not identified.
We have undertaken an audit of our COBE Spectrat processing at our Stem Cells and Immunotherapies (SCI) Department of the National Blood Service (NBS) in Bristol on all allogeneic bone marrow harvests collected between 1 January 2003 and 31 October 2005 and, because there were many more, on all autologous collections between 1 April 2004 and 31 December 2004. The objectives were (1) to compare the performance against published results and (2) to investigate factors that might influence MNC and CD34 þ cell recovery, including RBC, MNC and CD34 þ cellular composition, and environmental factors such as transit and storage conditions. Here, we describe the outcome of this audit and make recommendations for optimizing MNC and CD34 þ cell recoveries during COBE Spectrat processing for volume reduction and RBC depletion.
Materials and methods

Bone marrow collections
All bone marrow harvests were collected with written, fully informed consent for processing, testing and subsequent storage of their stem cells. In total, 88 bone marrow collections were included in the study, of which 25 were autologous and 63 were allogeneic donations. Of these, 47 were collected locally in Bristol with assistance of NBS SCI laboratory staff. The NBS collections were taken from the posterior iliac crest under general anaesthesia. Anticoagulant, comprising ACD-A (1:7) and heparin (10 IU/ml), was added gradually to avoid exposure to high ACD-A concentrations. In most instances, the white blood count (WBC) in the bone marrow was determined approximately halfway through the collection procedure to allow an estimate of the end point volume required to give a nucleated cell dose of 3-4 Â 10 8 /kg recipient body weight. These bone marrow collections were transported to the processing laboratory at ambient temperature in insulated transit containers validated for transport of blood donations. In addition, 41 allogeneic donations were imported from other collection centres, of which 26 were within the UK, 10 from other European countries, four from the USA and one from Australia. In these cases, the collections were transported to the processing laboratory by courier in insulated transit containers according to World Marrow Donor Association (WMDA) recommendations. 6 The temperature during transit was recorded for one collection only. This was from Australia and ranged between 6 and 161C. A further nine of the 41 imported collections were transported chilled, although the temperature on receipt was recorded for only four and averaged 9.51C. Two collections were supplemented with RPMI-1640 medium. On receipt in the laboratory, the collections were evaluated to determine (1) the collection volume (ml), (2) the collection haematocrit (HCT), (3) the total nucleated cell count, (4) the MNC count and (5) the specific CD45 þ , CD34
þ and CD3 þ cell counts. The transit time was calculated as the time taken from the end of the harvest procedure to receipt in the processing laboratory. If processing could not be commenced immediately, collections were stored at 2-61C until processing could begin.
Processing using the COBE Spectra The COBE Spectra (COBE BCT Inc., Lakewood, CO, USA) was used with a single-stage WBC tubing set on the WBC programme using the bone marrow processing setting as described by the manufacturer. During the MNC collection, manual adjustment of pump rates was used to maintain the RBC/plasma interface within the WBC collection channel. The bone marrow processing was completed when (a) the MNC fraction reached 130 ml volume, (b) the bone marrow had re-circulated through the collection process five times or (c) WBC were no longer apparent in the collection chamber.
Cell counts, ABO typing and CD34
þ cell analysis Cell counts were measured using an ethylenediaminetetraacetic acid-anticoagulated sample with an LH750 Haematology Analyser (Beckman Coulter, High Wycombe, Buckinghamshire, UK) and by single-platform three-colour flow cytometry using an International Society of Hematotherapy and Graft Engineering gating strategy. 7 The CD45, CD34
þ and MNC cell counts were determined by flow cytometry. 8 The vital dye, 7-aminioactinomycin D (7-AAD) was used to exclude non-viable cells and an internal positive control 8 was included to ensure the assay was working optimally. Cell doses were calculated based on recipient body weight (kg) at the time of processing. MNC and CD34
þ recoveries in the final product were determined as a percentage of the initial starting dose.
Measurement of neutrophil engraftment
Neutrophil engraftment was measured as the number of days after infusion until the circulating peripheral blood neutrophil count reached 0.5 Â 10 9 /l for 3 consecutive days.
Statistical analyses
Results are expressed as mean7s.d. Statistical analyses were carried out using an unpaired two-tailed t-test to compare two means (http://home.clara.net/sisa/t-test.htm). Where the variances were significantly different (determined using the f test), the Welch's t-test was used. A P-value of o0.05 was considered significant, o0.01 very significant and o0.001 extremely significant. Calculations are presented to four significant figures.
Results
Characteristics of the bone marrow harvests before and after processing The overall characteristics of all bone marrow harvests audited are summarized in Table 1 . The initial bone marrow collections had a mean volume of 12507398 ml (range 396-2309 ml) and RBC content of 3417113 ml (range 99-607 ml). Following processing on the COBE Spectrat, the volume of the MNC fraction was 135732 ml (88.2 þ 4.4% volume depletion) with RBC volume of 5.073.8 ml (98.371.8% RBC depletion). The mean MNC and CD34 þ cell recoveries were 83.3718.5% (range 10-115%) and 88.1718.9% (range 10-116%), respectively. In total, 60 of the 63 allogeneic grafts and three of the 25 autografts were infused with the remaining 25 cryopreserved for future use. The mean CD34 þ cell dose infused was 4.774.0 Â 10 6 /kg and neutrophil engraftment at 0.5 Â 10 9 /l averaged 20.176.4 days. The overall CD45 þ cell viability was 97.871.19% as determined by flow cytometry using 7-AAD staining.
When the bone marrow harvests were divided into autologous versus allogeneic and on the basis of local or distant collection centre (Table 2) , the highest MNC (94.078.5%) and CD34 þ cell (99.777.6%) recoveries were obtained for allogeneic donations collected locally. Although the autologous donations were also all from local Bristol centres, when compared to the allogeneic collections from Bristol, they had significantly lower MNC recoveries Table 2 Environmental factors, cellular composition and processing outcomes that differed for donor type (allogeneic/autologous) and geographical distribution of the collection centres (80.4716.9%, P ¼ 0.0012) and lower CD34 þ cell recoveries (86.1716.2%, P ¼ 0.0006). These differences may be attributable to the longer storage times (7.49 versus 3.42 h, P ¼ 0.0536) and greater average age (8.82 versus 4.46 h, P ¼ 0.0466) of the autologous collections, although other differences identified in the composition of cells collected from patients with haematological disorders (e.g. HCT, MNC and CD34 þ cell content) may also be important contributors.
To analyse which of these factors were important, we compared similar harvests (namely the allogeneic harvests) from healthy donors that were collected locally (in Bristol) with those collected at other UK centres or from abroad and then processed at the Bristol laboratory. The lowest MNC and CD34 þ cell recoveries occurred with collections from mainland Europe (MNC, 63.3727.7%; CD34 þ cells, 70.0728.0%) and USA/Australia (MNC, 76.8723.1%; CD34 þ cells, 74.0723.5%). Figure 1 shows the relationship between the initial and recovered CD34 þ cell counts for allogeneic collections based on their geographical distribution. Allogeneic collections from the local Bristol centre showed a strong linear relationship (y ¼ Â 0.9681) with excellent data correlation R 2 ¼ 0.9784. The donations from other UK centres generally show CD34 þ cell recoveries close to the linear trend, whereas those from abroad more frequently fell below the trend line. Although we cannot exclude a collection centre effect, there were other environmental factors identified in the study, including transit and storage times, and overall age, that were significantly different ( Table 2 ) and are likely to account for the results. The time in 2-61C storage ranged between 0 and 22.4 h with a median for the allogeneic donations of 1.0 h. The majority of collections were processed soon after receipt in the laboratory with 50 stored for 3.5 h or less. The remaining 13 were stored overnight (413 h) for processing the following day. Those collections processed within 1 h of receipt (n ¼ 32) had cell recoveries of 85.0717.9% for MNC and 88.8720.1% for CD34 þ cells, whereas those in storage over 1 h (n ¼ 31) had MNC and CD34 þ cell recoveries only slightly lower at 83.9720.5% (P ¼ 0.8161) and 88.8720.1% (P ¼ 0.9970), respectively. To further support the observation that refrigerated storage did not significantly affect cell recovery, and to exclude the significant effect of transit times, the CD34 þ cell recoveries were compared for all collections that were in transit less than 2.25 h and were in storage for (a) less than 1 h (n ¼ 15), (b) between 1 and 16 h (n ¼ 20) and (c) over 16 h (n ¼ 9) (Figure 2) . The CD34 þ cell recoveries were 96.3710, 94.4712.9 and 90.3712.5%, respectively, and were not significantly different (P40.2082).
The overall age of the collections at the time of processing had a significant effect on both MNC (P ¼ 0.0175) and CD34 þ cell (P ¼ 0.0217) recoveries. Those collections less than 5.7 h old gave MNC and CD34 þ cell recoveries of 90.1710.1 and 94.6711.6%, respectively, whereas the recoveries fell to 78.6724.0% for MNC and 82.9724.7% for CD34 þ cells with older collections. Those between 0 and 5 h old (n ¼ 24) generated CD34 þ cell recoveries of 97.578.7%, whereas CD34 cell recoveries fell progressively to 86.3721.4% (n ¼ 23, 5-20 h old), and 79.4725.1% (n ¼ 16, 20-40 h old) as the collections aged (Po0.0264).
Effect of graft composition on cell recoveries for allogeneic collections
The concentration of MNC and CD34 þ cells (Table 3) , in the pre-processed bone marrows, had significant effects on both CD34
þ cell (Po0.0269) recoveries. Bone marrow collections with MNC concentrations above the median (36.6 Â 10 8 /l) gave better CD34 cell recoveries (95.1713.4 versus 82.72723.3%) than those with MNC concentrations below the median. Similarly, collections with CD34 þ cell concentration above the median (151.5 Â 10 6 /l) had recoveries 11.2% higher (95.5714.2 versus 84.3723.6) than those below the median. There was no effect of collection volume, RBC content, total MNC or total CD34 þ cell counts on CD34 þ or MNC cell recoveries (data not shown).
RBC crenation is linked to poor CD34
þ cell recoveries The reduced MNC and progenitor cell recoveries observed may reflect RBC degenerative changes, such as sphering and crenation, which can occur within a few hours of storage at room temperature. 10, 11 These effects are likely to interfere with the formation of the buffy layer with the affected RBCs likely to segregate with WBCs owing to their modified shape and density. The normal range for mean cell volume (MCV) is 9279 fl, 12 which was similar in our study (92.675.9 fl). After processing on the COBE Spectra, those collections with MCV less than 92 fl (n ¼ 33) had CD34 þ cell recoveries only 1.5% higher (89.4722.3 versus 87.9717.5%) than those collections with MCV less than 92 fl (n ¼ 29). Six collections had MCV above the normal range (101-108 fI) and these had CD34 recoveries 12.3% lower at 77.1723.8%. Further to this, collections with MCV above 92 fl had increased initial collection volumes (13437311 ml (n ¼ 29) versus 10817362 ml (n ¼ 33), P ¼ 0.0036). The reason for this correlation is not clear, but suggests that RBCs may be damaged as the bone marrow collections progress. Stained films of allogeneic bone marrow donations were reviewed to determine the extent of RBC crenation and 11 collections were shown to have 45% crenated RBC, 36 o5% crenated RBC and 16 were not tested. Those collections with crenated RBC had CD34 þ cell recoveries of 64.9732% compared to 93.8712.4% (P ¼ 0.0028) for those where crenated RBC were absent.
Discussion
This study supports the previous reports from Baker et al. 4 and Koristek and Mayer 5 that the COBE Spectrat can be used effectively to volume reduce and red cell deplete bone marrow collections. The final volume of the MNC fraction was 135732 ml and was equivalent to a mean volume depletion of 88.274.4%, which is sufficient to allow cryostorage of donations when necessary. Volume depletion was not affected by the environmental factors studied, but was significantly influenced by the initial harvest volume and the MNC and CD34
þ progenitor cell concentrations (data not shown). In addition, the mean RBC depletion of 98.371.8% equates to an average RBC volume of 5.073.8 ml and was sufficient to remove the risk of ABOinduced transfusion reactions in most cases. 9 The MNC and CD34 þ cell recoveries achieved for autologous and allogeneic collections combined were 83.3718.5% (range 10-115%) and 88.1718.9% (range 10-116%), respectively, and these compare favourably with those from the previous studies. 4, 5 As reported previously, 4, 5 there was considerable variation in both MNC and progenitor cell recoveries. In the present study, MNC and CD34 þ progenitor cell recoveries ranged between 10 and 116% for both MNC and CD34 þ cells. The influence of environmental factors, such as time in transit, time in refrigerated storage and overall age, and the cellular composition of the donations was investigated to identify possible explanations for the wide range of cell recoveries.
The most significant environmental factor affecting both MNC (P ¼ 0.0060) and CD34 þ cell (P ¼ 0.0059) recoveries was time in transit. Cell recoveries for allogeneic collections in transit over the median time of 3.42 h were on average 13.3% lower for MNC and 13.9% lower for CD34 þ progenitor cells than those collections in transit less than the median. Further to this, the CD34 þ cell recoveries became progressively lower as the transit time increased declining from 99.777.8% for 2 h transit times to 73.2723% for over 12 h transit times.
We hypothesized that reduced MNC and progenitor cell recoveries observed as the harvests aged might reflect RBC degenerative changes, such as sphering and crenation, which can occur within a few hours of storage at room temperature. 10, 11 An examination of the extent of RBC crenation revealed that those collections with crenated RBC had CD34 þ cell recoveries of 64.9732% compared to 93.8712.4% (P ¼ 0.0028) for those where crenated RBC were absent. These degenerative changes to RBCs are known to be reduced by refrigerated storage between 2 and 61C, 10, 11, 12, 13 and this may explain the beneficial effect of storage observed in our study, where both MNC and CD34 þ progenitor cell recoveries were protected by refrigeration. In line with previous findings, 14 there was no apparent effect of refrigerated storage on CD34 þ viability of the allogeneic bone marrow grafts. Neutrophil engraftment was not significantly different (P ¼ 0.8959) for collections stored for less than 1 h when compared with those stored for more than 1 h (19.574.2 versus 19.376.8 days). Further to this, a total of 11 allogeneic collections were stored refrigerated overnight before processing and neutrophil engraftment at 0.5 Â 10 9 /l was still reached within 19.974.7 days.
The overall age of the collections also had a significant effect on MNC and CD34 þ progenitor cell recoveries, although to a lesser extent than the time in transit. Collections that were less than the median age of 5.7 h before processing had MNC and CD34 þ progenitor cell recoveries 11.5 and 11.7% higher, respectively, when compared to collections over 5.7 h old. The overall age of the collections resulted from a combination of both transit and storage times and, as refrigerated storage on receipt of the harvest did not significantly reduce MNC or CD34 þ cell recoveries, this most likely accounts for the effect of age being smaller than transit time.
There was no correlation between neutrophil engraftment with either MNC or CD34 þ cell recovery or with refrigerated storage. Only six of the 88 collections gave CD34 þ cell recoveries below 50% ranging between 10 and 48.5%. In order to recover sufficient cells for transplantation, the COBE Spectrat processing residues from five of these six harvests were processed again using the COBE 2991 according to the manufacturer's instruc- tions and overall CD34 þ cell recoveries of 88.2711.9% were achieved (data not shown). As such, the low CD34 recoveries obtained in the first processing run for these six patients did not directly impact on the CD34 þ progenitor cell dose at the time of infusion. The RBC content was higher after processing on the COBE 2991 at 49.5713.2 ml and, despite ABO incompatibility in two of the transplants, no adverse effects occurred during the infusions. The incidence of severe ABO-induced transfusion reactions after incompatible RBC transfusion is o32%, 15 and factors such as the recipient's antibody titre, and the volume and rate of the infusion are likely to affect the incidence of adverse reactions. 9 It is common practice to transport bone marrow collections between the collection and transplant centres at ambient temperatures. Our studies suggest that transit from other UK centres (4.671.9 h transit time) can reduce MNC and CD34 þ progenitor cell recoveries when processed on the COBE Spectrat by an average of 10%. Collections transported from other European countries (9.572.8 h transit time) had average MNC and CD34 þ cell recoveries that were 29.7% lower. As storage of the collections at 2-61C did not appear to significantly reduce MNC or CD34 þ cell recoveries, refrigerated transit of collections may be beneficial. During the audit period, all but 10 of the 41 imported products were transported at ambient temperatures, although refrigerated transport at 2-61C was requested in all cases. Of the 10 collections transported chilled, the temperature was measured during transit for only one, and on receipt in only four cases with only one being between 2 and 61C on receipt. There was no significant difference (P ¼ 0.7614) in the CD34 þ cell recovery between the 10 collections chilled during transit and the remaining 31 collected outside the Bristol area, although further studies using collections where temperatures are recorded during transit are required.
In conclusion, the COBE Spectra can be used to reduce both the volume and RBC content of bone marrow collections with mean RBC depletion and CD34 þ cell recoveries of 98.371.8 and 88.1718.9%, respectively. Time in storage and time to processing following harvest affected CD34
þ cell recoveries and this may reflect metabolic damage to RBCs associated with room temperature storage. In line with existing WMDA recommendations, 6 this study confirms that the time in transit between the collection and transplant centres should be minimized and, once received in the processing centre laboratory, collections should be processed as soon as possible. Refrigeration between 2 and 61C during transit is likely to be beneficial and, where processing cannot be performed immediately, collections should be stored refrigerated overnight to preserve RBC and maximize MNC and CD34 þ cell recovery.
